Recurrence of FSGS after Kidney Transplantation in Adults

Author:

Uffing AudreyORCID,Pérez-Sáez Maria José,Mazzali MarildaORCID,Manfro Roberto C.,Bauer Andrea CarlaORCID,de Sottomaior Drumond Frederico,O’Shaughnessy Michelle M.,Cheng Xingxing S.,Chin Kuo-Kai,Ventura Carlucci G.,Agena FabianaORCID,David-Neto EliasORCID,Mansur Juliana B.ORCID,Kirsztajn Gianna MastroianniORCID,Tedesco-Silva Helio,Neto Gilberto M.V.,Arias-Cabrales CarlosORCID,Buxeda AnnaORCID,Bugnazet Mathilde,Jouve ThomasORCID,Malvezzi PaoloORCID,Akalin Enver,Alani Omar,Agrawal Nikhil,La Manna Gaetano,Comai Giorgia,Bini Claudia,Muhsin Saif A.,Riella Miguel Carlos,Hokazono Silvia R.,Farouk Samira S.,Haverly Meredith,Mothi Suraj Sarvode,Berger Stefan P.ORCID,Cravedi PaoloORCID,Riella Leonardo V.ORCID

Abstract

Background and objectivesFSGS recurrence after kidney transplantation is a major risk factor for graft loss. However, the natural history, clinical predictors, and response to treatment remain unclear because of small sample sizes and poor generalizability of single-center studies, and disease misclassification in registry-based studies. We therefore aimed to determine the incidence, predictors, and treatment response of recurrent FSGS in a large cohort of kidney transplant recipients.Design, setting, participants, & measurementsThe Post-Transplant Glomerular Disease (TANGO) project is an observational, multicenter, international cohort study that aims to investigate glomerular disease recurrence post-transplantation. Transplant recipients were screened for the diagnosis of idiopathic FSGS between 2005 and 2015 and details were recorded about the transplant, clinical outcomes, treatments, and other risk factors.ResultsAmong 11,742 kidney transplant recipients screened for FSGS, 176 had a diagnosis of idiopathic FSGS and were included. FSGS recurred in 57 patients (32%; 95% confidence interval [95% CI], 25% to 39%) and 39% of them lost their graft over a median of 5 (interquartile range, 3.0–8.1) years. Multivariable Cox regression revealed a higher risk for recurrence with older age at native kidney disease onset (hazard ratio [HR], 1.37 per decade; 95% CI, 1.09 to 1.56). Other predictors were white race (HR, 2.14; 95% CI, 1.08 to 4.22), body mass index at transplant (HR, 0.89 per kg/m2; 95% CI, 0.83 to 0.95), and native kidney nephrectomies (HR, 2.76; 95% CI, 1.16 to 6.57). Plasmapheresis and rituximab were the most frequent treatments (81%). Partial or complete remission occurred in 57% of patients and was associated with better graft survival.ConclusionsIdiopathic FSGS recurs post-transplant in one third of cases and is associated with a five-fold higher risk of graft loss. Response to treatment is associated with significantly better outcomes but is achieved in only half of the cases.

Funder

Harvard Catalyst

National Center for Advancing Translational Sciences

Harvard University

Safra Foundation

Nephcure Foundation

Publisher

American Society of Nephrology (ASN)

Subject

Transplantation,Nephrology,Critical Care and Intensive Care Medicine,Epidemiology

Cited by 113 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3